Sarcoidosis, Pulmonary Clinical Trial
Official title:
A Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary Sarcoidosis
Patients with sarcoidosis need treatment options that effectively control their disease
without causing undesirable side effects. An appealing strategy is to repurpose existing
drugs which possess beneficial immune modulating activity and are safe for long-term use.
Recently, increased activity of the mTOR intracellular signalling pathway in inflammatory
cells has emerged as a key driver of granulomatous inflammation in mouse models and patients
with sarcoidosis. The macrolide antibiotic azithromycin directly inhibits mTOR activity in
inflammatory cells, making it a prime target for drug repurposing in sarcoidosis.
Azithromycin has an acceptable tolerability profile when used for long-term treatment of
other chronic respiratory disease Single centre open label clinical trial of oral
azithromycin 250 mg once daily for 3 months in 20-30 patients with pulmonary sarcoidosis.
The Investigator have opted for an open label study because this will be the first study of
azithromycin in sarcoidosis. Trial assessments will be performed according to standards of
Good Clinical Practice with assessments at baseline, 1, and 3 months. All other clinical
care, investigations, and treatment (if indicated) will remain the responsibility of the
treating physician and based on clinical MDT consensus decisions.
Disease behavior in sarcoidosis is variable and difficult to predict. Spontaneous improvement
may occur, but even then evidence of persistent low grade granulomatous inflammation is
common and disabling symptoms such as fatigue may persist. Patients with milder chronic
sarcoidosis may suffer significant symptoms and disability, but active monitoring and
supportive care are the only currently suitable management options. Recurrence after
remission is a problem, with some patients suffering from chronic ill health, progressive
disease and fibrosis, potentially leading to organ failure and death or transplantation.
Management is further complicated because some patients with symptomatic, progressive
sarcoidosis have a high burden of granulomatous disease, often affecting the lungs, whereas
other patients have limited disease in a dangerous location such as the heart or nervous
system.
Cure is not a realistic option whilst the cause(s) of sarcoidosis remain unknown. Ideally,
treatment should be aimed at preventing or slowing progression to irreversible fibrosis and
organ failure, reducing symptoms, and improving quality of life. The evidence that currently
used treatments achieve these aims is weak, and the risk of adverse effects is concerning for
patients and may outweigh perceived benefits. Treatment with corticosteroids is suppressive
rather than curative, and guidelines recommend at least 1 years' therapy for patients with
progressive disease. In the BTS sarcoidosis study, long term corticosteroids given to
patients with non-resolving pulmonary disease after six months' initial observation improved
lung function and chest x-ray appearances by a small amount. Importantly, of patients who
were given early steroids for troublesome symptoms, almost half were still taking steroids 5
years later. Yet whether steroids prevent fibrosis or improve clinically meaningful outcomes
that are important to patients in the longer term is unknown. Worryingly, there is evidence
that early steroid therapy may promote more aggressive disease later on. Side effects of
steroid therapy are often distressing and disfiguring, and sometimes serious or fatal. When
sarcoidosis is refractory to steroid treatment, second line immunomodulators such as
methotrexate, azathioprine, or mycophenolate are commonly prescribed based on their efficacy
in treating rheumatic diseases, and are recommended in guidelines. In sarcoidosis, the best
evidence is that they are steroid sparing (i.e. permit a lower dose of corticosteroid to be
used). As with steroids, long term benefits have not been demonstrated and liver and bone
marrow toxicity is a concern, requiring regular blood testing.
Whilst a unifying cause of sarcoidosis remains elusive, it has been established that
inflammatory cells including T lymphocytes, monocytes, and macrophages become hyper-activated
in the lungs and peripheral blood. Recently, using mouse models it has been shown that
chronic signalling through the mTOR complex 1 (mTORC1) in macrophages pathway drives the
formation of sarcoid-like granulomas that closely mimic non-resolving sarcoidosis in humans.
mTOR (mammalian/mechanistic target of rapamycin) links growth factors and availability of
amino acids to protein synthesis and cell growth, proliferation, and differentiation. mTOR
activity and gene targets correlating to sarcoidosis progression in lung biopsies have
implicated a potential role for targeting mTOR in human disease. These datasets indicate a
key role for mTOR pathways and the metabolic status of tissue macrophages in triggering and
driving disease pathology.
The macrolide antibiotic azithromycin is immunomodulatory and anti-bacterial, both of which
are plausible beneficial properties in sarcoidosis. Many studies have implicated bacteria as
triggers for sarcoidosis, and although convincing evidence implicating a specific organism is
lacking, improvements in sarcoidosis have been described in antibiotic combination studies
that included azithromycin. Beneficial immunomodulatory properties of macrolides became
apparent in the treatment of Asian diffuse panbronchiolitis, where reduced inflammatory
cytokine production in several cell types was demonstrated. Recently, it has been determined
that azithromycin directly suppresses mTOR activity in a subset of T lymphocytes (CD4+
T-cells).
Patients with pulmonary sarcoidosis need treatment options that effectively modulate disease
activity, reduce risk of disease progression, and improve symptoms and quality of life, with
an acceptable side effect profile. Azithromycin is a cheap, readily available generic drug.
Long term treatment with azithromycin has been shown to be safe in other chronic lung
diseases. Azithromycin is preferable to other macrolide antibiotics because of its safety
data for long term use, once daily administration, and lack of inhibition of liver CYP3A
isoenzymes. The safety profile of azithromycin makes it preferable to non-antibiotic
macrolide mTOR inhibitors such as rapamycin (sirolimus, used to treat transplant rejection))
and everolimus (an anti-cancer drug). Whether azithromycin will benefit patients with
sarcoidosis can only be answered definitively by a large multicenter clinical trial. The
Investigators proposed exploratory study aims to facilitate this aim by exploring mechanisms
and evaluating potential blood biomarkers, and assessing feasibility of a subsequent large
clinical trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03260556 -
Pirfenidone for Progressive Fibrotic Sarcoidosis
|
Phase 4 | |
Completed |
NCT05759221 -
Peripheral Airway Biopsy in Sarcoidosis
|
N/A | |
Completed |
NCT03336736 -
The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
|
||
Completed |
NCT03140644 -
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
|
N/A | |
Completed |
NCT03793439 -
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
|
Phase 1 | |
Recruiting |
NCT04895111 -
Endobronchial Ultrasound Strain Elastography in Sarcoidosis
|
||
Not yet recruiting |
NCT05910554 -
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05374447 -
Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy
|
N/A | |
Active, not recruiting |
NCT04314193 -
Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis
|
Phase 4 | |
Completed |
NCT03727451 -
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05746039 -
Feasibility of Semaglutide in Advanced Lung Disease
|
Phase 1/Phase 2 | |
Completed |
NCT04803617 -
Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
|
||
Recruiting |
NCT03145922 -
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
|
||
Completed |
NCT00279708 -
Atorvastatin to Treat Pulmonary Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05567133 -
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
|
||
Not yet recruiting |
NCT05291468 -
the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis
|
N/A | |
Completed |
NCT05311150 -
An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis
|
N/A | |
Completed |
NCT05811962 -
The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
|
||
Completed |
NCT03320070 -
Acthar Gel in Participants With Pulmonary Sarcoidosis
|
Phase 4 | |
Completed |
NCT03324503 -
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
|
N/A |